Edition:
United Kingdom

Avenue Therapeutics Inc (ATXI.OQ)

ATXI.OQ on NASDAQ Stock Exchange Capital Market

3.72USD
17 Aug 2018
Change (% chg)

$-0.08 (-2.11%)
Prev Close
$3.80
Open
$3.77
Day's High
$3.77
Day's Low
$3.72
Volume
553
Avg. Vol
8,628
52-wk High
$6.90
52-wk Low
$3.24

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics Reports Q2 Loss Per Share $0.45
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.45.AS OF JUNE 30, 2018, AVENUE'S CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $8.9 MILLION.  Full Article

Avenue Therapeutics Reports Positive Topline Phase 3 Data For Intravenous Tramadol In The Management Of Postoperative Pain
Monday, 21 May 2018 

May 21 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FOR INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - INITIATION OF SECOND PIVOTAL PHASE 3 TRIAL PLANNED FOR Q3 OF 2018.AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO REPORTS OF DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL.AVENUE THERAPEUTICS INC - IV TRAMADOL 25 MG TREATMENT ARM GENERALLY DISPLAYED INTERMEDIATE RESULTS THAT FELL BETWEEN 50 MG AND PLACEBO ARMS.AVENUE THERAPEUTICS - ANTICIPATE FILING NDA FOR IV TRAMADOL WITH U.S. FDA IN LATE 2019.  Full Article

Avenue Therapeutics Files For Mixed Shelf Offering Of Up To $75 Mln
Friday, 13 Apr 2018 

April 13 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $75 MILLION - SEC FILING.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Avenue Therapeutics reports Q3 loss per share $0.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.30.  Full Article

Avenue therapeutics reports Q2 loss per share $0.70
Friday, 11 Aug 2017 

Aug 11 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics reports second quarter 2017 financial results and recent corporate highlights.Q2 loss per share $0.70.  Full Article

Avenue Therapeutics ic files for IPO of up to $50 mln
Monday, 22 May 2017 

May 22 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc files for IPO of up to $50 million - sec filing.Avenue Therapeutics Inc - expect the public offering price to be between $9.00 and $11.00 per share.Avenue Therapeutics Inc - have applied to list our common stock on the nasdaq capital market under the symbol “atxi.”.Avenue Therapeutics Inc - raymond james, national securities corporation are underwriters to the ipo.Avenue Therapeutics Inc - ipo price is estimated solely for the purpose of computing the amount of the registration fee.  Full Article